Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Shares Outstanding (Weighted Average) (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $30.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 547.76% to $30.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.4 million through Dec 2025, up 547.76% year-over-year, with the annual reading at $30.4 million for FY2025, 547.76% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $30.4 million in Q4 2025 for Camp4 Therapeutics, up from $22.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $30.4 million in Q4 2025 to a low of $394976.0 in Q4 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $10.0 million across 3 years, with a median of $2.6 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 25.73% in 2024 and later soared 4379.93% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $394976.0 in 2023, then surged by 1087.44% to $4.7 million in 2024, then soared by 547.76% to $30.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CAMP at $30.4 million in Q4 2025, $22.6 million in Q3 2025, and $20.2 million in Q2 2025.